Cambridge study unlocks weight-loss drug paradox

demoduck.co.uk editorial team 2026-07-24 10:42 4 min read

A middle-aged man sitting on his bed injecting insulin into his abdomen area.

The apparent contradiction at the heart of several new weight-loss drugs may come down to where they act in the brain. Cambridge researchers found that activating one receptor in the brainstem and blocking the same receptor in the hypothalamus can both suppress appetite—but through different routes.

The findings, published in Nature Metabolism on 24 July 2026, could help scientists design combinations that produce greater weight loss with fewer unwanted effects. However, the University of Cambridge study was conducted in mice and does not establish treatment choices for people.

More than a billion people worldwide live with obesity, which is associated with higher risks of type 2 diabetes, cardiovascular disease and cancer. Medicines including Wegovy and Ozempic have changed treatment by stimulating the glucagon-like peptide 1 receptor, known as GLP-1R, to reduce appetite and improve blood sugar control.

Opposite drug actions reach different brain regions

The puzzle concerned a second protein switch called the glucose-dependent insulinotropic polypeptide receptor, or GIPR. Some medicines, including Mounjaro and Zepbound, stimulate this receptor. MariTide, an emerging treatment currently in phase 3 clinical trials, blocks it.

Despite acting in opposite ways, both approaches have been associated with weight loss. The Cambridge team found that their effects depend on which brain circuit is being targeted.

Activating GIPR in the brainstem suppressed appetite and reduced weight in the mice. The brainstem, located above the spinal cord, is involved in appetite and nausea.

Cambridge study unlocks weight-loss drug paradox

Blocking GIPR worked through the hypothalamus, a region central to hunger and body-weight regulation. The researchers concluded that antagonism in this area releases a biological “brake” that would otherwise limit the brainstem’s response to signals of fullness.

The result is not that the receptor behaves inconsistently. Instead, the same receptor performs different functions in separate parts of the brain.

Engineered mice exposed the two appetite pathways

Researchers at the University of Cambridge’s Institute of Metabolic Science used genetically engineered mice to isolate the relevant circuits. One group lacked GIPR in the brainstem, another lacked it in the hypothalamus, and a control group had no such modification.

The animals received different combinations of a GIPR agonist, which activates the receptor; a GIPR antagonist, which blocks it; and a GLP-1-based drug. Researchers measured food intake, body weight, fat mass, glucose control and brain activity.

Comparing the groups allowed the team to trace appetite suppression from GIPR agonists to the brainstem and the effect of antagonists to the hypothalamus. Blocking GIPR also appeared to strengthen the response to experimental drugs targeting the amylin receptor.

Combination treatments could target more than one circuit

The findings offer a biological explanation for the design of MariTide, which combines GIPR antagonism with GLP-1 receptor stimulation. They also suggest that blocking GIPR could potentially reinforce more than one class of anti-obesity medicine.

Dr Jo Lewis, the study’s first author at the Institute of Metabolic Science, said identifying the brain circuits that respond to these medicines could support drugs that deliver more weight loss with fewer side effects. The research also places the brain—not only the gut or pancreas—at the centre of how these treatments influence appetite and food intake.

That distinction matters when developing combination therapies. A drug that blocks a receptor in one circuit may complement another medicine working through a separate appetite pathway, rather than simply duplicating its action.

Mouse findings still require confirmation in people

The experiments explain the receptor’s region-specific effects in genetically modified mice. They do not show that the same mechanisms operate identically in the human brain or demonstrate how much additional weight loss a particular combination would produce in patients.

Nor does the study provide human evidence about dosing, tolerability or long-term side effects. Those questions must be resolved through clinical trials before the proposed circuit-based approach can shape routine treatment.

The Medical Research Council and Wellcome funded the research. MariTide’s phase 3 programme will provide the next human test of whether combining GLP-1 stimulation with GIPR blockade can translate this brain-circuit explanation into effective obesity treatment.

Source: University of Cambridge Research News

Context & actions About this article

Source check Source trail

This report is based on the University of Cambridge account of a mouse study published in Nature Metabolism on 24 July 2026.

Checks

Confirmed that the experiments used genetically engineered mice rather than human particip...
Distinguished GIPR activation in the brainstem from GIPR blockade in the hypothalamus.
Checked the reported drug examples against the mechanisms described in the source.
Retained the source’s phase 3 status for MariTide without presenting clinical effectivenes...

University of Cambridge Research News Check independent coverage